SCHEMBL238141

SCHEMBL238141

COC(=O)c1cc(C(=O)c2ccc(O)cn2)ccc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B14 Q9BPX1 6/20 0.46
HSD17B1 P14061 3/20 0.46
HSD17B2 P37059 3/20 0.46
MAPK1 P28482 2/20 0.46
KDM4E B2RXH2 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA7 P43166 3/20 0.41
CA9 Q16790 3/20 0.41
CA14 Q9ULX7 3/20 0.41
PDK2 Q15119 1/20 0.40
PDK4 Q16654 1/20 0.40
LTC4S Q16873 5/20 0.40
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL236631 0.86 MAPK1 (0.44) HSD17B14HSD17B1HSD17B2MAPK1KDM4E
SCHEMBL237279 0.86 LTC4S (0.47) HSD17B14HSD17B1HSD17B2MAPK1KDM4E
SCHEMBL238194 0.81 LTC4S (0.47) HSD17B1HSD17B2MAPK1LTC4S
SCHEMBL236387 0.79 LTC4S (0.66) LTC4S
SCHEMBL238157 0.78 MAOB (0.52) LTC4S
SCHEMBL236386 0.77 P4HTM (0.48) CA1CA2LTC4S
SCHEMBL11972220 0.75 CA12 (0.67) HSD17B1HSD17B2KDM4EL3MBTL1CA12
SCHEMBL1401556 0.75 KDM4E (0.58) KDM4EL3MBTL1CA12CA1CA2
SCHEMBL238839 0.75 OPRK1 (0.39) MAPK1KDM4EL3MBTL1CA12CA1
SCHEMBL164488 0.74 MAPK1 (0.67) MAPK1KDM4EL3MBTL1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406223-A2 BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS Biolipox AB (SE) 2012-01-18 EP disclosed
US-20120004244-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed
US-20110319431-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2011-12-29 US disclosed
WO-2010103297-A2 BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS BIOLIPOX AB (SE) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004244-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors LTC4S, LTB4R2, LTB4R HSD17B14 192/4885HSD17B1 249/4885HSD17B2 335/4885
US-20110319431-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors LTC4S, LTB4R2, LTB4R HSD17B14 264/4885HSD17B1 340/4885HSD17B2 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.